$NVOX
  • About us

        • URAX Daily Target 2X Long Uranium ETF

          LLYX Daily Target 2X Long LLY ETF

          MSTX Daily Target 2X Long MSTR ETF

          SMST Daily Target 2X Short MSTR ETF

          SMCX Daily Target 2X Long SMCI ETF

          AVGX Daily Target 2X Long AVGO ETF

          NVOX Daily Target 2X Long NVO ETF

          RIOX Daily Target 2X Long RIOT ETF

          SOFX Daily Target 2X Long SOFI ETF

          QQQY Nasdaq 100 Enhanced Options 0DTE Income ETF

          WDTE S&P 500 Enhanced Options 0DTE Income ETF

          IWMY R2000 Enhanced Options 0DTE Income ETF

          SPYT S&P 500 Income Target ETF

          USOY Oil Enhanced Options Income ETF

          QQQT NASDAQ 100 Income Target ETF

          QTUM Quantum ETF

          SIXG Connective Technologies ETF

          HDRO Next Gen H2 ETF

          CRUZ Hotel, Airline, and Cruise ETF

          XMAG Large Cap Ex-Magnificent Seven ETF

          Product Guide Materials
  • Insights
  • News
  • Contact Us

NVOX

$

Defiance Daily Target 2X Long NVO ETF

Name(Required)
Distribution Rate *
-%
As of —
Distribution Frequency
Monthly
30-Day SEC Yield **
-%
As of —
rating

Defiance Daily Target 2X Long NVO ETF

The Defiance Daily Target 2X Long NVO ETF (the “Fund”) seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of NOVO Nordisk A/S – ADR (NYSE: NVO) (the “Underlying Security” or “NVO”). NVOX does not invest directly in NOVO. Because the Fund seeks daily leveraged investment results, it is very different from most other exchange-traded funds. It is also riskier than alternatives that do not use leverage. There is no guarantee that the Fund will meet its stated objective. The fund should not be expected to provide 2 times the cumulative return of NOVO for periods greater than a day.

The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. An investor could lose the full principal value of his/her investment within a single day.

Underlying Stock: NOVO Nordisk A/S – ADR

NOVO Nordisk A/S (“Novo Nordisk”) is a Danish global pharmaceutical company. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically to provide diabetes care and other chronic conditions like obesity, hemophilia, and growth disorders. It is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The Fund will seek to achieve its objective with respect to Novo Nordisk’s American Depositary Receipt (NYSE: NVO).

Fund Details

 Data as of 01/16/2025
Net Assets $2.43M
Premium/discount 0.34%
NAV $10.81
Closing Price $10.84
Shares Outstanding 225,000
Median 30 Day Spread 0.33%
Fund inception 12/2/2024
Ticker NVOX
Primary Exchange NASDAQ
CUSIP 88636J246
Fund Holdings 5
NAV Symbol NVOX.NV
Expense Ratio 1.29%
30 Day SEC Yield*
* Yield as of

NVOXMarket Price

Performance

YTD 1 Month 3 Months 6 Months Since Inception
Total Return NAV (%) xx.xx% xx.xx% xx.xx% xx.xx% -41.27%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx% -41.41%
1 Year 3 Years 5 Years Since Inception
Total Return (%) xx.xx% xx.xx% xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx%
2024
Total Return NAV(%) xx.xx%
Market Price (%) xx.xx%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share’s portion of the fund’s underlying assets and cash at the end of the trading day.

Top Holdings

View full holdings
Name Symbol Stock price % Net assets Shares Held Market Value
Novo-nordisk A S Adr Swap – L – Mar 670100205-TRS-01/05/26-L $83.07 105.42% 30,799 $2,558,473
Novo-nordisk A/s-spons Adr Nomura 670100205-TRS-01/12/26-L $83.07 84.54% 24,700 $2,051,829
First American Government Obligations Fund 12/01/2031 FGXXX $100.00 18.23% 442,463 $442,463
Novo Nordisk A/s NVO $83.07 10.22% 2,987 $248,130
Cash & Other Cash&Other $1.00 -118.42% -2,873,961 $-2,873,961
Data as of 01/17/2025. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
View full holdings

Distribution

Declaration Date Ex-Div Date Record Date Payable Date Amount ($)
— — — — —
Distribution Rate *
As of —		 -%
Distribution Frequency Monthly
30-Day SEC Yield **
As of —		 -%